Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints cancer immunotherapy experts

Ronald Levy, Zelig Eshhar and Inder Verma will offer expert advice to US biotech

Ronald Levy, Kite Pharma Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.

Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.

Their expertise will help the US biotech develop medicines that activate the body's T cells to fight tumours.

Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.

"Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said Dr Aya Jakobovits, president and CEO of Kite.

Article by
Thomas Meek

12th August 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics